MegaPro Biomedical Co PEG

Cosa fa MegaPro Biomedical Co? MegaPro Biomedical Co Ltd is a biotechnology company based in Zhubei, Taiwan, operating within the health care sector. The company has a workforce of 20 employees and completed its initial public offering (IPO) on October 19, 2021. Its primary focus is the development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's product portfolio includes several compounds designated as MPB-1514, MPB-1523, MPB-1734, and MPB-2043. MPB-1514 is designed for intravenous treatment of anemia associated with chronic kidney disease. MPB-1523 is intended for intravenous diagnosis of hepatocellular carcinoma. MPB-1734 targets solid tumors through intravenous administration. MPB-2043 is used for intravenous diagnosis of metastases in peripheral lymph nodes near cancerous sites. The company maintains a website at https://www.megaprobio.com/ for further information. MegaPro Biomedical Co Ltd operates under the ticker symbol 6827.TWO and is registered with ISIN TW0006827009. It is headquartered in Zhubei, Hsinchu, Taiwan, and is engaged in the development of advanced biotechnological solutions for medical applications. MegaPro Biomedical Co è una delle aziende più popolari su Eulerpool.com.